drugset / Trial / NCT00219284
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
RandomizedParallel-groupOpen-labelTreatment
Summary
To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and entacapone.
Timeline
- Start
- 2005-01
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entacapone | Small molecule | 200 mg | — |
| Background | Carbidopa | Unknown | 12.5 mg | — |
| Background | Carbidopa | Unknown | 25 mg | — |
| Background | Carbidopa | Unknown | 37.5 mg | — |
| Background | Levodopa | Unknown | 50 mg | — |
| Background | Levodopa | Unknown | 100 mg | — |
| Background | Levodopa | Unknown | 150 mg | — |